Status:
COMPLETED
Specific Clinical Experience Investigation for Long-term Use of Exenatide (Byetta Subcutaneous Injection)
Lead Sponsor:
AstraZeneca
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
Brief Summary
The purpose of this investigation is to describe general safety profile of type II Diabetes Mellitus (DM) Japanese patients under exenatide therapy in real world medical practices
Detailed Description
Specific Clinical Experience Investigation for long-term use of exenatide (Byetta subcutaneous injection).
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- \- Patient diagnosed with Type 2 Diabetes Mellitus and who is naive patient with Byetta.
Exclusion
Key Trial Info
Start Date :
February 13 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 3 2019
Estimated Enrollment :
2948 Patients enrolled
Trial Details
Trial ID
NCT01817569
Start Date
February 13 2011
End Date
October 3 2019
Last Update
July 20 2020
Active Locations (46)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Aichi, Japan, D5550C00001
2
Research Site
Akita, Japan, D5550C00001
3
Research Site
Aomori, Japan, D5550C00001
4
Research Site
Chiba, Japan, D5550C00001